Regeneron's blood cancer therapy faces setback as FDA raises trial concerns
Reuters
Published Mar 25, 2024 07:29AM ET
Updated Mar 25, 2024 10:26AM ET
(Reuters) -Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma on concerns over the progress of ongoing confirmatory trials.
The FDA said in its response letter that it needs more data from enrollments in dose-finding and confirmatory portions of trials, delaying its decision on the drug, while confirming no issues with clinical efficacy or safety, trial design, labeling or manufacturing.
The company was testing its experimental drug, odronextamab, in multiple late-stage trials in patients with follicular lymphoma and diffuse large B-cell lymphoma, the two most common subtypes of non-Hodgkin lymphoma.
Regeneron (NASDAQ:REGN) said "it was the first time" a CRL for this reason was issued by the U.S. Food and Drug Administration, which has been lately working to raise the bar for cancer drug developers seeking accelerated approval for their candidates.
Such approvals allow the agency to move therapies that target serious and life-threatening conditions to the market more quickly, but have been criticized because some drugs have later been proven to be ineffective.
Regeneron's shares fell marginally to $961.78 in early trading. The company was looking to expand its oncology portfolio with odronextamab, beyond its lone approved skin cancer drug, Libtayo
While odronextamab was on track to potentially become Regeneron's first blood cancer drug, it has a much smaller market opportunity of $200 million compared to other potential launches of the company as lymphoma is a competitive space, RBC Capital Markets analyst Brian Abrahams said.
Abrahams added that he does not believe this delay significantly impacts the company's fundamentals as odronextamab would have been a "marginal revenue driver".
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.